# Pfizer Pipeline

November 8, 2012

# Disclaimer

- As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information for candidates from Phase 3 through regulatory approval. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. The information contained on these pages is correct as of November 8, 2012.

- Visit Pfizer.com/pipeline, Pfizer's online database where you can learn more about our portfolio of new medicines and find out more about our Research and Development efforts around the world.

# Table of Contents

# Pfizer Pipeline Snapshot




Pipeline represents progress of R&D programs as of November 8, 2012

Included are 59 NMEs, 17 additional indications, plus 2 biosimilars

**Recent Approvals**

- **Xeljanz** (tofacitinib) for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate (U.S.)
- **Xalkori f**or treatment of previously treated ALK-positive advanced non-small cell lung cancer (EU)
- **Bosulif (bosutinib)** for treatment of previously treated chronic myelogenous leukemia (U.S.)
- **Inlyta (axitinib)** for treatment of advanced renal cell carcinoma after failure of prior systemic treatment (EU)




Pipeline represents progress of R&D programs as of August 9, 2012

Included are 65 NMEs, 20 additional indications, plus 2 biosimilars

**Recent Approval**

- **Lyrica** for treatment of central neuropathic pain due to spinal cord injury (U.S.)

# Pfizer Pipeline – November 8, 2012

| Therapeutic Area | Compound Name | Mechanism of Action (Phase 3 through regulatory approval) | Indication | Phase |
|---|---|---|---|---|
| **Cardiovascular and Metabolic Diseases** | Viviant | Selective Estrogen Receptor Modulator | Osteoporosis Treatment and Prevention (U.S.) | Registration |
| | Eliquis (apixaban) | Factor Xa Inhibitor | Prevention of Stroke and Systemic Embolism in patients with Nonvalvular Atrial Fibrillation (U.S./EU) | Registration |
| | apixaban | Factor Xa Inhibitor | Venous Thromboembolism Prevention (U.S.) | Phase 3 |
| | Eliquis (apixaban) | Factor Xa Inhibitor | Venous Thromboembolism Treatment | Phase 3 |
| | PF-04971729 | | Diabetes Mellitus-Type 2 | Phase 2 |
| | RN316 (PF-04950615) | | Hypercholesterolemia (Biologic) | Phase 2 |
| | PF-04937319 | | Diabetes Mellitus-Type 2 | Phase 2 |
| | PF-00489791 | | Diabetic Nephropathy | Phase 2 |
| | CVX 096 (PF-04856883) | | Diabetes Mellitus-Type 2 (Biologic) | Phase 1 |
| | PF-05231023 | | Diabetes Mellitus-Type 2 (Biologic) | Phase 1 |
| | PF-05175157 | | Diabetes Mellitus-Type 2 | Phase 1 |
| | PF-05335810 | | Hypercholesterolemia (Biologic) | Phase 1 |
| | PF-06282999 | | Acute Coronary Syndrome | Phase 1 |

New Molecular Entity

New Indication or Enhancement

# Pfizer Pipeline – November 8, 2012 (cont'd)

| Therapeutic Area | Compound Name | Mechanism of Action (Phase 3 through regulatory approval) | Indication | Phase |
|---|---|---|---|---|
| **Inflammation and Immunology** | tofacitinib (CP-690550) | JAK Inhibitor | Rheumatoid Arthritis (EU) | Registration |
| | tofacitinib (CP-690550) | JAK Inhibitor | Psoriasis (Oral) | Phase 3 |
| | tofacitinib (CP-690550) | JAK Inhibitor | Ulcerative Colitis | Phase 3 |
| | PF-04171327 | | Rheumatoid Arthritis | Phase 2 |
| | PF-05285401 | | Ulcerative Colitis (Biologic) | Phase 2 |
| | anrukinzumab (IMA-638) | | Ulcerative Colitis (Biologic) | Phase 2 |
| | PF-00547659 | | Crohn's Disease (Biologic) | Phase 2 |
| | PF-04236921 | | Crohn's Disease, Lupus, *Rheumatoid Arthritis (Biologic) | Phase 2 |
| | tofacitinib (CP-690550) | | Psoriatic Arthritis, Ankylosing Spondylitis, Psoriasis (Topical), Crohn's Disease | Phase 2 |
| | PF-06473871 (EXC 001) | | Dermal Scarring | Phase 2 |
| | PD-360324 | | Lupus (Biologic) | Phase 1 |
| | PF-05280586 | | Rheumatoid Arthritis (Biosimilar) | Phase 1 |

New Molecular Entity | New Indication or Enhancement | Biosimilar

* Note: Additional indications in Phase 1

# Pfizer Pipeline – November 8, 2012 (cont'd)

| Therapeutic Area | Compound Name | Mechanism of Action (Phase 3 through regulatory approval) | Indication | Phase |
|---|---|---|---|---|
| Neuroscience & Pain | tafamidis meglumine | Transthyretin (TTR) Dissociation Inhibitor | Transthyretin familial amyloid polyneuropathy (U.S.) | Registration |
| | Celebrex | COX-2 | Chronic Pain (U.S.) | Registration |
| | Remoxy | Mu-type opioid receptor (MOR-1) Agonist | Moderate to Severe Pain (U.S.) | Registration |
| | ALO-02 Oxycodone-naltrexone core | Mu-type opioid receptor (MOR-1) Agonist | Moderate to Severe Pain | Phase 3 |
| | Lyrica | Alpha-2 Delta Ligand | Peripheral Neuropathic Pain | Phase 3 |
| | Lyrica | Alpha-2 Delta Ligand | CR (once a day dosing) | Phase 3 |
| | tanezumab | Nerve Growth Factor Inhibitor | OA Signs and Symptoms (Biologic) | Phase 3 |
| | PF-02545920 | | Schizophrenia | Phase 2 |
| | PF-03049423 | | Stroke Recovery | Phase 2 |
| | tanezumab | | Chronic Pain (Biologic) | Phase 2 |
| | PF-05089771 | | Chronic Pain | Phase 1 |
| | PF-05236812 (AAB-003) | | Alzheimer's Disease (Biologic) | Phase 1 |
| | PF-04958242 | | Schizophrenia, Sensorineural Hearing Loss | Phase 1 |
| | PF-05212377 (SAM-760) | | Alzheimer's Disease | Phase 1 |
| | PF-05180999 | | Schizophrenia | Phase 1 |
| | PF-06273340 | | Acute and Chronic Pain | Phase 1 |

New Molecular Entity

New Indication or Enhancement

# Pfizer Pipeline – November 8, 2012 (cont'd)

| Therapeutic Area | Compound Name | Mechanism of Action (Phase 3 through regulatory approval) | Indication | Phase |
|---|---|---|---|---|
| Oncology | bosutinib | Abl and src-family kinase inhibitor | Treatment of Previously Treated Chronic Myelogenous Leukemia (EU) | Registration |
| | dacomitinib (PF-00299804) | pan-HER Inhibitor | Previously Treated Advanced Non-Small Cell Lung Cancer | Phase 3 |
| | Xalkori (crizotinib) | c-MET-ALK Inhibitor | ALK-Positive 1st and 2nd Line (supports full approval in the U.S.) Non-Small Cell Lung Cancer, *Cancer | Phase 3 |
| | Inlyta (axitinib) | VEGF Tyrosine Kinase Inhibitor | Renal Cell Carcinoma Adjuvant (Asia only) | Phase 3 |
| | Sutent | Multiple Tyrosine Kinase Inhibitor | Renal Cell Carcinoma Adjuvant | Phase 3 |
| | inotuzumab ozogamicin | | Aggressive Non-Hodgkin's Lymphoma (Biologic) | Phase 3 |
| | inotuzumab ozogamicin | | Acute Lymphoblastic Leukemia (Biologic) | Phase 3 |
| | Inlyta (axitinib) | | Liver Cancer | Phase 2 |
| | dacomitinib (PF-00299804) | | Cancer | Phase 2 |
| | PD-0332991 | | 1st Line Advanced Breast Cancer | Phase 2 |
| | CVX 060 (PF-04856884) | | Renal Cell Carcinoma, *Cancer (Biologic) | Phase 2 |
| | PF-05212384 | | Endometrial Cancer, *Cancer | Phase 2 |
| | PF-03084014 | | Cancer | Phase 1 |
| | PF-03446962 | | Cancer (Biologic) | Phase 1 |
| | PD-0325901 | | Cancer (in combination with PF-05212384) | Phase 1 |

* Note: Additional indications in Phase 1

New Molecular Entity

New Indication or Enhancement

# Pfizer Pipeline – November 8, 2012 (cont'd)

| Therapeutic Area | Compound Name | Mechanism of Action (Phase 3 through regulatory approval) | Indication | Phase |
|---|---|---|---|---|
| **Oncology (cont'd)** | PF-05082566 | | Cancer (Biologic) | Phase 1 |
| | PF-04605412 | | Cancer (Biologic) | Phase 1 |
| | PF-05280014 | | Metastatic Breast Cancer (Biosimilar) | Phase 1 |
| | PF-04449913 | | Acute Myelocytic Leukemia | Phase 1 |
| **Vaccines** | ACC-001 (PF-05236806) | | Alzheimer's Disease | Phase 2 |
| | ▶ MnB rLP2086 (PF-05212366) | | Adolescent and Young Adult Meningitis B | Phase 3 |
| | 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) (PF-06290510) | | Staph Aureus | Phase 2 |
| | PF-05402536 | | Smoking Cessation | Phase 1 |
| | ▶ PF-06425090 | | Clostridium Difficile Colitis | Phase 1 |

New Molecular Entity | New Indication or Enhancement | Biosimilar

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

# Pfizer Pipeline – November 8, 2012 (cont'd)

| Therapeutic Area | Compound Name | Mechanism of Action (Phase 3 through regulatory approval) | Indication | Phase |
|---|---|---|---|---|
| Other Areas of Focus | bazedoxifene-conjugated estrogens | Tissue Selective Estrogen Complex | Menopausal Vasomotor Symptoms (EU) | Registration |
| | Zithromax/chloroquine | 5-OS Ribosome Inhibitor | Malaria | Phase 3 |
| | bazedoxifene-conjugated estrogens | Tissue Selective Estrogen Complex | Menopausal Vasomotor Symptoms (U.S.) | Phase 3 |
| | bosutinib | | Autosomal Dominant Polycystic Kidney Disease | Phase 2 |
| | PF-00868554 (filibuvir) | | Hepatitis C Virus | Phase 2 |
| | tofacitinib (CP-690550) | | Transplant Rejection | Phase 2 |
| | PH-797804 | | Chronic Obstructive Pulmonary Disease | Phase 2 |
| | PF-06460031 (GMI-1070) | | Vaso-occlusive crisis associated with Sickle Cell Disease | Phase 2 |
| | PNU-100480 | | Tuberculosis | Phase 2 |
| | ►RN6G (PF-04382923) | | Age-Related Macular Degeneration (Biologic) | Phase 2 |
| | PF-03715455 | | Chronic Obstructive Pulmonary Disease | Phase 1 |
| | PF-05280602 | | Hemophilia (Biologic) | Phase 1 |
| | PF-06252616 | | Muscular Dystrophies (Biologic) | Phase 1 |

New Molecular Entity

New Indication or Enhancement

►Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

# Projects Discontinued from Development since August 9, 2012

| Compound Name | Mechanism of Action (Phase 3 through regulatory approval) | Indication | Phase |
|---|---|---|---|
| Taliglucerase alfa | Enzyme Replacement Therapy | Type 1 Gaucher Disease (Biologic) (EU) | Registration |
| Xiapex (EU) | Clostridial Collagenase for Injection | Peyronie's Disease (Biologic) (EU)<br><br>In November 2012, we and our alliance partner, Auxilium Pharmaceuticals, Inc. (Auxilium), announced that we are amending our collaboration agreement for the development, commercialization and supply of Xiapex in the EU and certain other European and Eurasian countries (the Collaboration Agreement). As a result of this amendment, the Collaboration Agreement will terminate no later than April 24, 2013. Prior to the mutual termination date, the parties will continue to perform all of their obligations as described in the Collaboration Agreement. After the termination date, rights to commercialize Xiapex in those markets and further development of the indication for Peyronie's disease will revert to Auxilium | Phase 3 |
| Inlyta (axitinib) | VEGF Tyrosine Kinase Inhibitor | Advanced Renal Cell Carcinoma in treatment-naïve patients | Phase 3 |
| Eraxis/Vfend | Beta-D Glucan Synthase Inhibitor, Cyp P450 Mediated Alpha-lanosterol Demethylation | Aspergillosis | Phase 3 |
| Eladur | | Chronic Pain | Phase 2 |
| PF-04691502 | | Endometrial Cancer, *Cancer | Phase 2 |
| OAP-189 (PF-05212389) | | Diabetes Mellitus-Type 2, Obesity (Biologic) | Phase 1 |
| PF-03882845 | | Diabetic Nephropathy | Phase 1 |

New Indication or Enhancement

New Molecular Entity

* Note: Additional indications in Phase 1